{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019659","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.241705+00:00","generated_at":"2026-06-15T09:31:21.988116+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcus Q1 net loss $80M, cash $1.0B; multiple Ph3 domvanalimab trials enrolling","bullets":["Revenue $25M (up from $18M YoY); net loss $80M vs $68M in Q1 2022.","Cash, equivalents and securities $1.0B; expected to fund operations into 2026.","Four Phase 3 and two Phase 2 trials enrolling for domvanalimab combinations in lung and GI cancers.","AB521 (HIF-2α inhibitor) dose-escalation enrolling 100mg; Phase 2 combo study in ccRCC expected Q3 2023.","Three new drug candidates advancing to clinic: AB598 (anti-CD39) Q2 2023, AB801 (Axl inhibitor) H2 2023, AB375 (KIT inhibitor) early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019659","json":"https://secwatch.observer/filing/0000950170-23-019659.json","markdown":"https://secwatch.observer/filing/0000950170-23-019659.md","text":"https://secwatch.observer/filing/0000950170-23-019659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023019659/0000950170-23-019659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023019659/rcus-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:31:21.988116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2dac008423ce7f7cb605dcc2630276db2f675180","claim":"Arcus Biosciences, Inc. reported the first quarter ended March 31, 2023 results: revenue $25 million.","evidence_excerpt":"cash in research and development activities. Cash, cash equivalents and marketable securities on-hand are expected to be sufficient to fund operations into 2026. • Revenues were $25 million for first quarter 2023, compared to $18 million for the same period in 2022. In first quarter 2023, Arcus recognized $17 million in license and development service revenues for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023019659/0000950170-23-019659-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$25 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}